What is we were immunoassay-guided for who to give vaccines, whether the vaccine was effective, when 1 dose was enough?
Just now, 10 days after my 2nd dose vaccine, I had a quantitative multiplex immune response panel, via finger stick, taking <15 mins, watched in real-time 1/
I'll go through the steps but the bottom line is that I fortunately had very high levels of IgG to #SARSCoV2 RBD (receptor binding domain), the S1 of there spike protein and the S2 portion of the spike protein 2/
Steps
1. My finger stick blood into a capillary tube
2. Put on a dedicated, reusable chip
3. Put into the machine
4. Assays quickly running /3
In real-time I am watching my IgG to RBD go off the chart
(top, draw blue line), 7 minutes in /4
And after buffers stay up there /5
I had a paired venipuncture sample run and the results were very similar /6
Note that I have IgG antibodies to 2 common cold coronaviruses (HKU1, NL63) that I didn't have when I had the same panel back in March (thread about that here)/ 7
The lack of a nucleocapsid IgG response is in keeping with the S-protein target of the vaccines

Let me make clear that I have no COI, no relationship with Genalyte /8
If this could scale to millions of test/ day, such an assay panel could used to assure vaccine efficacy, defer vaccines for people who've had covid-19, and test single dose strategies. ~ 70 million Americans have had covid, the assay picks up infections > 10 months /9

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Eric Topol

Eric Topol Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @EricTopol

13 Jan
1. If you thought yesterday's more than 4,400 deaths will be the worst of the American pandemic, or the previous >300,000 cases in a day, you're not paying attention.
We're already approaching 1% B.1.1.7 strain
blog.helix.com/b117-variant-u…
2. This strain's destiny is to become dominant here in the weeks ahead. That mean's going vertical. Look at Ireland with >40% B.1.1.7
3. We're not doing the vital things we need to do to go to full prevent mode
Read 6 tweets
8 Jan
Why it is time (never too late) to get super-serious
1. Holiday surge after holiday surge is small potatoes compared with a superspreader strain.
B.1.1.7 is here, <1%, but will be dominant in the weeks ahead
It is a strain, by definition:
jamanetwork.com/journals/jama/…
2. The "superspreader" strains B.1.1.7 and 501Y.V2
Because they are more infectious (X%, but much more than D614G ,which had only a modest transmission ⬆️)
More people will get sick
More people will get hospitalized
More people will get #LongCovid
More people will die
3. Over the next several weeks, these new strains will become the dominant ones in the United States, just as they have in the UK and other countries. Exponential spread. Why we need to contain the virus and vaccinate 24/7 like there's no tomorrow.
Read 6 tweets
6 Jan
If you want to know about #SARSCoV2 as it started and where it is going, you talk to @edwardcholmes, a leading evolutionary virologist @Sydney_Uni
medscape.com/viewarticle/94… @Medscape video and transcript
a 🧵 /1
Eddie's Jan 10th tweet that will go down in history since the virus sequence led to the design of mRNA vaccines 2 days later /2
Prof Holmes has been studying viruses for 30 years, in recent years a lot of metagenomic sequencing, the technique used to identify #SARSCoV2, and a major collaboration with Prof Zhang in Shanghai
time.com/collection/100… /3
Read 14 tweets
3 Jan
Connecting the dots between RSV, F, erection, S, and 2P's
1. The @McLellan_Lab work on RSV virus to stabilize the F protein (which may lead to successful vaccines)
From newyorker.com/magazine/2021/… @NewYorker by @lawrence_wright
2. The @ScienceMagazine paper in 2013 that was, in retrospect, a frontrunner for coronaviruses and #SARSCoV2 sharing the property of membrane fusion and the need to stabilized the fusion protein to get effective vaccines
science.sciencemag.org/content/sci/34…
3. That was by X-ray crystallography which didn't enable visualization of the spike (S) protein of coronaviruses until this @nature publication by @WardLab1 @McLellan_Lab @KizzyPhD and colleagues in 2016 via cryo-EM nature.com/articles/natur…
Read 6 tweets
1 Jan
On our new podcast, we interviewed @angie_rasmussen, one of the leading virologists, who has been a guiding light during the pandemic. Thread here to summarize, transcript and audio medscape.com/viewarticle/94… @cuttingforstone /1
Current status
"We're essentially experiencing the equivalent of a 9/11 every day in terms of number of deaths; our hospital systems are overburdened. ...We're going to be dealing w/ this for some time to come, even after people get the vaccine, certainly #LongCovid is real." /2
On her strong efforts for dispelling misinformation
"My philosophy about public health is that you can't have it without the engagement of the public. And my philosophy about communication is that information empowers people to decide for themselves" /3
Read 12 tweets
30 Dec 20
The Phase 3 @moderna_tx #SARSCoV2 vaccine trial is published @NEJM nejm.org/doi/full/10.10…
The historic cumulative event curve
Subgroup analysis, maintenance of efficacy across the board
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!